Expression and role of HEG1 in non-small cell lung cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035343

Enrollment

Unknown

Registered

2020-08-09

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Gold Standard:Pathology

Index test:HEG1 concentration

Eligibility

Sex/Gender

All

Age

25 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Patients with primary lung cancer (clinical staging - stage) undergoing surgical resection; (2) None of the patients received radiochemotherapy and targeted interventional therapy before surgery; (3) All patients signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Abnormal liver and kidney function; (2) complicated with other malignant tumors; (3) complicated with bronchiectasis, pulmonary abscess, asthma, COPD, pulmonary fibrosis and other pulmonary diseases.

Design outcomes

Primary

Measure	Time frame
HEG1 levels in the blood;MRNA and protein expression levels of HEG1 in lung cancer and adjacent tissues;	—

Countries

China

Contacts

Public ContactWei Han

Qingdao Municipal Hospital

sallyhan1@163.com+86 18561857838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026